Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLoNg: pembrolizumab and radiotherapy for oligometastatic head and neck squamous cell carcinoma
2023-504478-39-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-504478-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504478-39-00.